Hemogenyx Pharmaceuticals (LON:HEMO) Announces Quarterly Earnings Results

Hemogenyx Pharmaceuticals (LON:HEMO) announced its quarterly earnings data on Thursday. The company reported GBX (170.60) EPS for the quarter, Digital Look Earnings reports.

Hemogenyx Pharmaceuticals Trading Down 0.7%

Hemogenyx Pharmaceuticals stock traded down GBX 5 during mid-day trading on Thursday, hitting GBX 675. The company’s stock had a trading volume of 40,874 shares, compared to its average volume of 31,326. Hemogenyx Pharmaceuticals has a one year low of GBX 124 and a one year high of GBX 1,800. The stock has a market cap of £43.37 million, a PE ratio of -2.92 and a beta of 1.54. The company has a 50 day moving average of GBX 978.21 and a 200-day moving average of GBX 834.51. The company has a debt-to-equity ratio of -440.54, a quick ratio of 6.72 and a current ratio of 0.43.

Hemogenyx Pharmaceuticals Company Profile

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants.